Skip to main content

The Pharmacokinetics of Sublingual Atropine

The study of the pharmacokinetics of sublingual atropine drops will help in determining the safety of sublingual atropine. The effect on saliva secretion, blood pressure, pulse rate, and vision will also studied.

Sublingual atropine drops are used frequently in the treatment of clozapine-induced hypersalivation and drooling. To date, no studies have investigated the pharmacokinetics of sublingually administered atropine and if it is different from that of oral atropine.

Participants will be having a single dose of 0.6mg sublingual atropine drops on day 1. On day 2 at least 4 days after day 1 dose: a single 0.6mg dose of atropine tablet to be swallowed. On day 3 at least 4 days after day 2 dose: a single 1.2mg dose of sublingual atropine drops. Participation in all 3 days is ideal but not a must for participation.

Sequential venous blood will be collected over 10 hours at the Charles Perkins Centre-Camperdown, NSW.

A small compensation for travel expenses will be provided at the end of each study day.

Ethics committee approval number: HREC/18/RPAH/687


You may be eligible to participate in this study if:

  • you are between 18 and 50 years old
  • you are not pregnant and not breast feeding
  • you are able to consent for participation in the study, and
  • your nominated GP doesn’t raise any medical or mental health issues that prohibits the participation of the potential participant in the study. If no GP in nominated by the POTENTIAL participant the research medical chief investigator will decide on suitability for participation based on screening blood test and ECG results.

How to participate

If you are interested in assisting with this important and exciting area of research, please contact the study principal investigator and coordinator Omar Mubaslat on 9515 8145 or